Biotechnology

Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ap...

2023-01-09 20:00 1460

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

MELBOURNE, Australia, Jan. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41 st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco. As part of the Company's presentation (available to view o...

2023-01-09 06:37 2212

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S

BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...

2023-01-08 14:17 3157

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...

2023-01-07 17:29 3478

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...

2023-01-06 21:00 1821

Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism

Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...

2023-01-06 18:00 1484

SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock

- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...

2023-01-06 09:10 1345

Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, will present a...

2023-01-05 23:30 2389

AMR Action Fund Announces Investment in BioVersys AG

Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ --  The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicr...

2023-01-05 20:00 7500

Shine-On Biomedical Co., Ltd. Accorded the International Innovation Awards 2022 for TROY CAR EXOs

SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place inBangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, ind...

2023-01-05 18:20 2373

Oneness Biotech Co., Ltd.'s FESPIXON® Honored at the International Innovation Awards 2022

SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place inBangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, ind...

2023-01-05 17:46 2556

Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems

SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Novogene , a leading provider of genomic services and solutions, announced the addition of Illumina's latest high-throughput sequencing systemNovaSeq™ X Plus and PacBio's Revio™ long-read sequencing sys...

2023-01-05 17:00 2371

Aurisco cooperates with Cytiva to build its first Oligo FlexFactory for commercial production

* Located in Yangzhou of East China, Aurisco's new commercial manufacturing site is expected to produce 200 kilograms of oligonucleotides each year. * Through the cooperation with Cytiva, Aurisco will deliver more oligonucleotides to its global customers with better quality and efficiency. SH...

2023-01-05 14:36 1584

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...

2023-01-05 09:00 1180

Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...

2023-01-05 09:00 2194

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms * WuXi Biologics will receive an upfro...

2023-01-05 08:30 3645

Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-01-05 08:00 3444

DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...

2023-01-05 08:00 1858

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 2319

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 2249
1 ... 90919293949596 ... 279